Prospects for the use of statins in antiviral therapy

Inhibitors of hydroxymethylglutaryl-CoA reductase, in addition to suppressing cholesterol synthesis, have an antiviral effect. Clinical studies shown efficacy statins against COVID-19, HCV, HBV, RSV, HIV, influenza viruses. The ability inhibit viruses, as well Ebola, Zika, Dengue, Coxsackie, rotaviruses, ADV, HDV, HHV was experimentally confirmed. Statins can also enhance the effects drugs, making them more effective treating infections. Therefore, use complex therapy viral infections is promising. In addition, role T-cell leukemia and herpesviruses, HPV development atherosclerosis has been identified, so treatment necessary correct endothelial dysfunction that occurs under influence Since activity retroelements are evolutionarily related exogenous viruses increases with aging, it suggested retrotransposons be targets for statins. This evidenced by a change expression non-coding RNAs action statins, since key sources retroelements. property may additional factor prescription increase life expectancy, prevention atherosclerosis, pathological activation causes aging. Viruses, like retroelements, involved pathogenesis malignant neoplasms, which their effectiveness effect anticancer overcoming chemoresistance (similar potentiation drugs). One mechanisms this on